Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.180 -0.060 (-4.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 486,242
Open 1.220
Bid (Size) 1.160 (1)
Ask (Size) 1.210 (14)
Prev. Close 1.240
Today's Range 1.140 - 1.250
52wk Range 0.9501 - 31.74
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
Via ACCESSWIRE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE

Performance

YTD
-86.99%
-86.99%
1 Month
-72.37%
-72.37%
3 Month
-88.34%
-88.34%
6 Month
-72.06%
-72.06%
1 Year
-95.82%
-95.82%

More News

Read More
JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Why Jaguar Health (JAGX) Stock Is Down 15%
Via Benzinga
Jaguar Health Reports Second Quarter 2024 Financial Results
Via ACCESSWIRE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Via ACCESSWIRE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
Via ACCESSWIRE
Why Jaguar Health Stock Is Crashing
Via Benzinga
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Via ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Via ACCESSWIRE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
Via ACCESSWIRE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Via ACCESSWIRE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
Via ACCESSWIRE
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Is Azitra (AZTR) Stock Up 315% Today?
Via InvestorPlace
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading
Via InvestorPlace
Topics ETFs
Why Is Serve Robotics (SERV) Stock Down Today?
Via InvestorPlace
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
Via InvestorPlace
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Via Benzinga
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
Via ACCESSWIRE
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Via ACCESSWIRE
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
Via ACCESSWIRE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.